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INTRODUCTION
Colorectal cancer (CRC) was 
the second most frequent can-
cer in Europe in 2004, responsi-
ble for 13% (376,400) of all inci-
dent cancer cases. It is also the 
second most frequent cause of 
cancer mortality in Europe, with 
11.9% (203,700) annual deaths 
(1). When localized, CRC is often 
a curable disease, but the overall 
prognosis is determined by the 
extent of local and particularly 
metastatic tumour spread. The 
disease outlook is relatively poor, 
because advanced disease is a 
signiﬁcant cause of worldwide 
cancer-related mortality. Thus, 
estimated 5-year survival rates 
range from nearly 90% in stage 
I disease (Dukes’ A) to less than 
10% in patients with metastatic 
disease (Dukes’ D) (1). Compre-
hensive cancer care in the 21st 
century is dependent on a multi-
disciplinary approach to patients 
with malignant disease. Large 
bowel cancer is no exception, as 
there is increasing clinical trial 
data supporting multimodal treat-
ment for both localized and ad-
vanced tumours. This review will 
focus on the important aspects 
in CRC including the latest treat-
ment strategies (chemotherapy, 
radiotherapy and the targeted 
therapies).
EPIDEMIOLOGY AND INCI-
DENCE
Colorectal cancer is an important 
public health problem; it is one of 
the leading causes of cancer mor-
tality in the industrialized world. 
There are nearly one million new 
cases of CRC diagnosed world-
wide each year and half a mil-
lion deaths (2). When detected     www.ljm.org.ly   
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early, CRC is highly treatable and 
curable. Globally, the incidence 
of CRC varies 10-fold, with the 
highest incidence rates in North 
America, Australia, and northern 
and western Europe; developing 
countries have lower rates, par-
ticularly Africa and Asia (3). These 
geographic differences appear to 
be attributable to differences in 
dietary and environmental expo-
sures that are imposed upon a 
background of genetically deter-
mined susceptibility.
Age is a major risk factor for 
sporadic CRC. It is a rare diag-
nosis before the age of 40, the 
incidence begins to increase sig-
niﬁcantly between the ages of 
40 and 50, and age-speciﬁc inci-
dence rates increase in each suc-
ceeding decade thereafter (4). 
Recent reports show that, in the 
USA, it is the most frequent form 
of cancer among persons aged 
75 years and older (5). Given that 
the majority of cancers occur in 
elderly people and with the age-
ing of the population in mind, this 
observation gives further impetus 
to investigating prevention and 
treatment strategies among this 
subgroup of the population (5). 
The lifetime incidence of CRC in 
patients at average risk is about 5 
%, with 90 % of cases occurring 
after age 50 (6, 7). The incidence 
is higher in patients with speciﬁc 
inherited conditions that predis-
pose them to the development of 
CRC.
AETIOLOGY
Most colon cancers arise from 
adenomatous polyps. About 5% 
of adenomatous polyps are esti-
mated to become malignant and 
this process takes approximately 
10 years (5). The most important 
etiological factor to date is ge-
netic predisposition. Genetic al-
teration such as mutation of the 
APC (adenomatous polyposis 
coli) tumour suppressor gene, 
K-ras proto-oncogene and P53 
has been demonstrated to lead 
to polyps and cancer formation in 
the large intestine (8-10). Under-
standing of the molecular patho-
genesis of CRC (both sporadic 
and inherited) is evolving rapidly. 
These ﬁndings have led to the 
identiﬁcation of several speciﬁc 
genetic disorders, all of which are 
inherited in an autosomal domi-
nant fashion, that are associated 
with a very high risk of develop-
ing colon cancer. Sporadic CRC 
is estimated to account for 80% 
of all CRCs and hereditary forms 
account for the remaining 20% 
(11). The hereditary syndromes 
include familial adenomatous 
polyposis (FAP) which accounts Libyan Journal of Medicine, Volume 1, 2006
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for 1% of all CRC (12) hereditary 
nonpolyposis colon cancer (HN-
PCC) which accounts for 5-10% 
of all CRC (13), and familial co-
lon cancer (FCC) which accounts 
for the remaining 10-15%. FCC is 
most likely to be of multifactorial 
origin and remains largely unex-
plained at this time.
Epidemiologic studies suggest 
that several exogenous agents, 
for example red meat and to-
bacco smoking, may increase the 
risk of developing CRC. Others, 
such as NSAID’s (non-steroidal 
anti-inﬂammatory drugs), vegeta-
bles and hormone replacement 
therapy, may reduce the risk (14). 
Knowledge of agents responsible 
for development of CRC is still 
limited. High energy intake, espe-
cially from saturated fat, seem to 
be a deﬁnite risk factor and high 
consumption of dietary ﬁber and 
vegetables seem to be protective, 
especially when combined with 
physical exercise (15-19). How-
ever there is still much contro-
versy concerning this “fat–ﬁber” 
hypothesis. It suggests that the 
epithelium in the colon and rec-
tum will be exposed to mutagens 
for longer times due to prolonged 
transit time in the gut caused by 
fat-rich and low-ﬁber diets com-
bined with low physical activity 
(20).
ADENOMA-CARCINOMA SE-
QUENCE
Colorectal carcinomas arise 
through a series of well-charac-
terised histopatho-logical chang-
es as the result of speciﬁc genetic 
‘hits’ at certain oncogenes and tu-
mour suppressor genes. At least 
four sequential genetic changes 
need to occur to ensure CRC 
evolution: The luminal third of the 
colonic crypt begins to proliferate 
and this is thought to be due to a 
mutation in the APC gene found 
in chromosome number 5. Per-
sistence of this proliferation leads 
to the formation of an adenoma, 
which is benign, but premalignant. 
This stage is reversible as can be 
observed by the administration of 
sulindac (NSAID) (21). Ras on-
cogenes, especially Ki-ras, are 
thought to be responsible for the 
change from adenoma to adeno-
carcinoma. During neoplastic mi-
tosis, accurate replication of the 
genome is not guaranteed. Small 
pieces of DNA are lost and even 
entire chromosomes may be lost. 
Thus, these lesions have genetic 
instability. Sometimes, the asym-
metric mitosis results in the loss 
of critical genetic loci that are re-
sponsible for the restraint of cellu-
lar proliferation. As the neoplastic 
mitotic divisions continue, genetic 
instability progressively increas-    www.ljm.org.ly   
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es leading to cells with a greater 
growth advantage and ultimately, 
invasive abilities are obtained.
STAGING
Cancer can grow inward toward 
the lumen of the colon or rectum, 
and-or outward through the walls 
of these organs. Advanced dis-
ease can cause perforation of the 
bowel, leading to infection. Metas-
tasis of the disease may occur to 
the lymph nodes, liver, lung, peri-
toneum, ovaries, and brain. Ac-
curate staging of CRC (see table 
below) can help to predict overall 
prognosis and select appropriate 
treatment options. It is also criti-
cal to evaluate the overall results 
of treatment.
DIAGNOSIS
The main symptoms of CRC 
are changes of bowel habit and 
bleeding. If the tumour is located 
in the rectum there may be fresh 
red blood on the stool surface, 
while haemorrhagic 
proximal lesions re-
sult in dark faeces. 
The changes in bow-
el habit may involve 
any type of change 
in frequency or con-
sistency of the stool. 
Diarrhoea, constipa-
tion, increased pas-
sage of ﬂatus and/ 
or urgency may oc-
cur. Other symptoms 
are abdominal pain, 
anaemia and weight 
loss may suggest a 
more advanced tu-
mour.
Investigative proce-
dures usually start with per rec-
tum examination, rectoscopy and 
checking for occult blood in fae-
ces. Frequently a radiological in-
vestigation with air-contrast bari-
um enema is performed combined 
with endoscopic investigation of Libyan Journal of Medicine, Volume 1, 2006
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the rectum and colon. Biopsies 
for histopathological evaluation 
are mandatory for making a ﬁrm 
diagnosis. Ultrasound, CT and 
MRI are methods used to deter-
mine the extent of tumour growth 
locally and to investigate if there 
is metastatic spread to the lymph 
nodes, liver or other organs. In 
rectal cancer MRI can detect tu-
mour penetration through the rec-
tal wall, into the perirectal tissue, 
as well as the presence of local 
lymph node metastases in 75% 
of the patients (23).
MANAGEMENT OF COLOREC-
TAL CANCER
Curative management of CRC 
relies primarily on surgical resec-
tion, possibly accompanied by 
adjuvant chemotherapy. In rectal 
cancer, radiation therapy is also 
used.
SURGERY
About 50% of patients with newly 
diagnosed colon cancer are cured 
with surgery alone, predominant-
ly patients with stage I and II dis-
ease.
Primary Tumour: The primary 
therapy for adenocarcinoma of 
the colon and rectum is surgical 
removal of the bowel segment 
containing the tumour, the ad-
jacent mesentery, and draining 
lymph nodes. The type of surgi-
cal resection depends on the tu-
mour’s anatomic location. Right 
or left hemicolectomy is the surgi-
cal treatment of choice in patients 
with right- or left-side colonic tu-
mours, respectively. Tumours in 
the sigmoid colon may be treated 
by wide sigmoid resection. 
Major recent advances have im-
proved understanding of rectal 
anatomy and the biology of the ex-
traluminal spread of rectal cancer. 
In addition, the end-to-end anas-
tomotic stapling device has made 
it easier to perform lower rectal 
anastomosis. However, inad-
equate resection and injudicious 
use of these devices has resulted 
in an unacceptably high pelvic re-
currence rate. Appropriate proxi-
mal, distal, and radial resection 
margins with nodal clearance en-
compassed within the mesorectal 
fascial envelope has resulted in 
pelvic recurrence rates of 10% or 
lower (24). The technique of to-
tal mesorectal excision has been 
championed by Heald and is now 
accepted throughout the Western 
world. Total mesorectal excision 
should be performed for cancers 
of the middle and distal third of the 
rectum. The technique involves 
resection of the rectum and en-    www.ljm.org.ly   
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tire mesorectum down to the pel-
vic ﬂoor with preservation of the 
pelvic sympathetic and parasym-
pathetic nerves to preserve blad-
der and sexual function. Although 
a 2 cm distal margin is preferred, 
a margin of 1 cm is acceptable, 
since most rectal cancers do not 
exceed 1 cm of distal submucos-
al extension (25). Cancer of the 
upper third of the rectum should 
be resected with generous subto-
tal mesorectal excision; the distal 
rectal resection margin should be 
5 cm with accompanying subtotal 
mesorectal resection of at least 
5 cm from the distal edge of the 
tumour. Tumours at or just above 
the sphincter mechanism are 
treated by abdominoperineal re-
section; total mesorectal excision 
is an essential part of this resec-
tion. In a multivariate analysis, 
the most consistent predictors of 
long-term survival were stage of 
the primary tumour, percentage 
of tumour involvement (26) (with 
fewer than three metastases and 
small tumours conferring a better 
prognosis), and disease-negative 
surgical margins. 
Metastases: Surgical excision is 
the standard of care in patients 
with resectable liver and pulmo-
nary metastases from CRC ow-
ing to the potential for long-term 
survival after complete resection 
in these cases and to the fact that 
without surgery, such disease 
remains incurable at present. 
Twenty-ﬁve percent of CRC pa-
tients present with liver metas-
tases (synchronous); about 50% 
of CRC patients develop liver 
metastases after surgical resec-
tion of the primary tumour (meta-
chronous) (27). In six series with 
more than 100 patients each, 5-
year survival rates of from 25% 
to 39% and a median survival of 
longer than 2 years were reported 
after resection of liver metastases 
(26, 28-31). 
CHEMOTHERAPY
Adjuvant chemotherapy
Nearly half of the patients under-
going apparently curative resec-
tion of bowel cancer are destined 
to relapse and eventually die with 
either locally recurrent or distant 
metastatic disease. This is due to 
the presence of residual micro-
metastases (Sub-clinical) invis-
ible at the time of surgery. The 
aim of adjuvant chemotherapy is 
to eradicate these micro-metas-
tases and thereby prevent future 
relapse.
A large randomised trial was con-
ducted comparing surgery alone 
and surgery plus 5-FU/levamisol 
in patients with Dukes’ C CRC. It Libyan Journal of Medicine, Volume 1, 2006
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demonstrated that the group re-
ceiving chemotherapy had a 33% 
lower risk of death and 41% less 
recurrence risk (The Intergroup 
Study (32)). Other randomised 
trials have also shown increased 
disease-free and overall survival 
after adjuvant treatment with 5-
FU/FA, which confer an absolute 
survival beneﬁt of 5-6% (33, 34). 
As a result of many randomised 
trials it is now accepted that pa-
tients with Dukes’ C carcinoma 
of the colon should be offered 5-
ﬂuorouracil based adjuvant chem-
otherapy if they are ﬁt to receive it 
(35). Other newer chemotherapy 
agents may be more effective in 
the adjuvant setting and proved 
to have a safer proﬁle like the use 
of Capecitabine (Xeloda) as an 
alternative to the 5-FU, also the 
last year’s ﬁndings marked a shift 
in the standard of care in adjuvant 
therapy in CRC and extended by 
utilising the combination therapy 
in form of 5-FU+LV+Oxaliplatin 
regimen (FOLFOX) and the bene-
ﬁts appear clearly in terms of Dis-
ease Free Survival (DFS) (36).
The role of chemotherapy in the 
adjuvant setting is delineated 
in Dukes’ C CRC, with an abso-
lute survival beneﬁt of 6-9% at 5 
years, but not as yet established 
in Dukes’ B where the absolute 
survival beneﬁt is only between 
2-3%. The standard procedure 
nowadays in the USA and Eu-
rope is to use the FU/LV for six 
months period (34, 37). However 
this standard is limited to stage III 
patients, whereas the manage-
ment of stage II patients remains 
a controversial issue owing to a 
limited beneﬁt in survival as men-
tioned in the previous paragraph. 
Combined Chemotherapy for Ad-
vanced and Metastatic CRC
The outlook for patients with ad-
vanced CRC has improved sub-
stantially with the introduction of 
the combination regimens (38, 
39) with median survival times 
almost doubling over the past 10 
years (40). The administration of 
5-Fluorouracil (5-FU) and Irinote-
can (Camptosar) or Oxaliplatin 
(Eloxatin) are now widely used 
for the treatment of advanced 
CRC. The drugs work by different 
mechanisms, and colon cancers 
do not generally manifest cross-
resistance to the two agents when 
they are used serially. More re-
cently, combination regimens with 
irinotecan, 5-FU, and Leucovorin 
(LV) have produced survival ben-
eﬁts superior to 5-FU and leucov-
orin. In Europe, irinotecan is most 
frequently combined with an infu-
sion regimen of 5-FU, whereas in 
the United States bolus 5-FU has 
been favoured until recently (41).     www.ljm.org.ly   
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European data, evaluating infu-
sional 5-FU with irinotecan and 
Leucovorin (FOLFIRI) followed 
by the infusional 5-FU schedule 
with oxaliplatin (FOLFOX) at the 
time of disease progression ver-
sus the opposite sequence of the 
combinations, have shown an 
overall median survival exceed-
ing 20 months regardless of the 
sequence, representing the best 
survival statistics for patients with 
advanced and metastatic CRC 
(42).
FOLFOX and FOLFIRI appear to 
be the most effective in terms of ef-
ﬁcacy and tolerability. Larger ran-
domised trials comparing these 2 
regimens are ongoing. Tournig-
and and his colleagues evaluated 
the FOLFOX and FOLFIRI regi-
mens to ﬁnd the best sequence for 
treating patients with metastatic 
CRC. (40) The study showed that 
a sequence of ﬁrst line FOLFOX 
followed by second line FOLFIRI 
resulted in a similar survival time 
to that produced by the reverse 
sequence. However, as at least 
30% of patients did not receive 
second-line therapy, the authors 
highlighted the importance of 
choosing the most appropriate 
ﬁrst-line therapy. Although both 
ﬁrst line therapies achieved simi-
lar response rates (FOLFIRI 56% 
vs FOLFOX 54%), second line 
FOLFIRI achieved a signiﬁcant-
ly lower response rate than did 
FOLFOX (4% vs 15%). The tox-
icity proﬁles for the two regimens 
were also different. As expected 
from previous studies, grade 
¾ mucositis, nausea/vomiting, 
and grade 2 alopecia were more 
common with FOLFIRI, whereas 
grade ¾ neutropenia and neuro-
sensory toxicity were more com-
mon with FOLFOX. At the present 
time some data coming from dif-
ferent recent clinical trials, which 
incorporated the targeted therapy 
in their protocols ,suggests that a 
longer survival advantage of 24 
months has been achieved.
RADIOTHERAPY
Radiotherapy as a deﬁnitive or 
adjuvant modality for colon can-
cer lying above peritoneal re-
ﬂection has not gained popular-
ity. Radiotherapy has two major 
limitations when applied to colon 
cancer: A poorly deﬁned target, 
since the colon is mobile, and the 
fact that dose-limiting structures 
surround the colon (i.e., large 
amount of small bowel, kidney, 
and liver). An exception is oc-
casionally given to carcinoma of 
the cecum with extension into the 
abdominal wall, where it is possi-
ble to deﬁne the area at risk, par-
ticularly if it is marked with clips. Libyan Journal of Medicine, Volume 1, 2006
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Radiotherapy is used, however, 
for palliation in colon cancer. To 
date, no randomised study re-
sults are available to substantiate 
the use of adjuvant radiotherapy 
for colon cancer. Chemotherapy 
remains the most important adju-
vant treatment for colon cancer.
The role of radiotherapy in rectal 
cancer is more justiﬁed anatomi-
cally. The rectum is a relatively 
ﬁxed structure in the pelvis and 
it is situated below the organs of 
limited tolerance to radiotherapy. 
It is feasible to deliver reasonably 
high doses of radiotherapy with-
out severe toxicity.
ADJUVANT RADIOTHERAPY
Preoperative radiotherapy
Preoperative radiotherapy for 
clinically resectable tumours: Pr-
eoperative radiotherapy in these 
circumstances may have theoret-
ical advantages. It may be more 
effective in killing tumour cells, 
since better vascularized and ox-
ygenated cells are more sensitive 
to radiotherapy. Radiotherapy 
has a better deﬁned target when 
the tumour is in place. Preopera-
tive radiotherapy usually utilizes 
short regimens and therefore is 
more convenient for patients and 
more cost effective (1 week of 
treatment, dose 5 x 5 Gy/week).
Preoperative radiotherapy for 
unresectable tumours: For most 
surgeons and oncologists, the 
term “unresectable” indicates 
that the tumour is ﬁxed to adja-
cent pelvic structures. The goal of 
radiotherapy here is to shrink the 
tumour and to make it surgically 
resectable. A substantial dose of 
radiotherapy should be delivered 
for two reasons:
A. Radiotherapy should affect 
gross macroscopic disease (un-
like postoperative adjuvant ra-
diotherapy, which is dealing with 
microscopic disease only).
B. In the case of a failure to facili-
tate resectability, radiotherapy will 
be the principal treatment modal-
ity, which can at least delay the 
progression of the disease.
Postoperative radiotherapy
In 1990, the National Institute of 
Health Consensus Conference 
on Adjuvant Therapy of Large 
Bowel Cancer evaluated the ef-
fectiveness of adjuvant treatment 
for rectal cancer. Their conclusion 
was that “combined postoperative 
chemotherapy and radiotherapy 
improves local control and surviv-
al in Stage II and III patients and 
is recommended (43).     www.ljm.org.ly   
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Pre and postoperative radiother-
apy trials
There has been much debate 
about whether adjuvant radio-
therapy should be administered 
pre- or postoperatively. The ﬁrst 
randomised trial directly compar-
ing preoperative and postopera-
tive radiotherapy is the Swedish 
Uppsala trial. In this trial 471 pa-
tients with resectable rectal and 
rectosigmoid cancer were ran-
domly allocated to receive either 
preoperative short-term high-
dose irradiation (25.0 Gy in one 
week) for all patients or prolonged 
postoperative radiotherapy (60 
Gy in seven to eight weeks) only 
for patients with a Dukes B or C 
lesion. After a minimum follow-up 
of ﬁve years, the local recurrence 
rate was  signiﬁcantly lower after 
preoperative than after postop-
erative radiotherapy (13 % vs. 
22 %; p= 0.02) (44). The cancer 
Collaborative Group carried out a 
meta-analysis of 22 randomized 
controlled trials comparing the 
outcomes of surgery for rectal can-
cer combined with pre- or postop-
erative radiotherapy with those of 
surgery alone (6350 patients in 14 
preoperative and 2157 patients 
in 8 postoperative trials) (45). 
The investigators concluded that 
overall survival was only slightly 
better in those patients receiv-
ing radiotherapy compared with 
those allocated to surgery alone, 
(mortality 62% vs. 63%, p=0.06). 
The rates of apparently curative 
surgery were not increased by 
radiotherapy (86% controls and 
85% radiotherapy). However, the 
yearly risk of recurrence in the 
group receiving preoperative ra-
diotherapy was 46% lower than 
that in the group receiving surgery 
alone (p=0.00001) and 37% lower 
in the group receiving postopera-
tive radiotherapy (p=0.002). The 
meta-analysis also demonstrated 
that preoperative radiotherapy 
was more efﬁcacious at lower 
biological doses than the post-
operative radiotherapy studies 
(range 30-37 Gy vs. 35-43 Gy), 
which correlates with the ﬁndings 
of the Swedish Uppsala trial (44). 
Preoperative therapy over a week 
is also easier to administer than 
postoperative treatment over 5 or 
6 weeks. Other advantages in-
clude increased tumour radiosen-
sitivity, decreased tumour seed-
ing at surgery and increased rate 
of sphincter sparing.
In a recent trial conducted by the 
Dutch CRC Group 1861 patients 
were randomized to receive ei-
ther preoperative radiotherapy (5 
Gy for 5 days) followed by total 
mesorectal excision or total me-
sorectal excision alone. A signiﬁ-
cant decrease was found in the Libyan Journal of Medicine, Volume 1, 2006
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rates of local recurrence in the 
radiotherapy arm compared with 
that in controls (2.4% radiothera-
py vs. 8.2% surgery). The rates 
of overall survival at 2 years were 
not signiﬁcantly different (82% 
radiotherapy vs. 81.8% control) 
athough a longer follow-up period 
might demonstrate differences in 
survival (46).
Various schedules of radiothera-
py and chemoradiotherapy have 
been studied, with encourag-
ing results. (47) The lyon R0-04 
Phase II study treated 40 patients 
with operable T3/4, N1/2, M0 rec-
tal cancers with radiotherapy 50 
Gy over 5 weeks together with two 
cycles of oxaliplatin and infused 
5FU in weeks 1 and 5 (48). Objec-
tive clinical responses were seen 
in 75%, and complete histologic 
response was seen in 15%. Com-
plete resection was performed in 
all patients. A randomised study 
(German trial) of pre-operative vs 
post-operative chemoradiation 
enrolled 421 patients with en-
dorectal ultrasound-staged T3/4 
or node positive rectal tumours. 
(49) There was no difference in 
overall survival at 5 yrs, however, 
there was a statistically signiﬁ-
cant reduction in cumulative local 
relapse in the preoperative treat-
ment arm (6 vs 13%, P=0.0006). 
In addition, both short and long 
term toxic effects were reduced 
in patients randomised to pre-op-
erative treatment. The Polish trial 
demonstrated that patients who 
were randomized to short-course 
radiotherapy with immediate sur-
gery had a similar rate of sphinc-
ter preservation (61%) to those 
receiving long-course chemora-
diotherapy and delayed surgery 
(59%) (50). 
In CR07 trial: Pre-operative ra-
diotherapy and selective post-op-
erative chemo-radiotherapy have 
been studied in patients with rec-
tal cancer The preliminary results 
from this trial was presented in 
June 2006 during the ASCO an-
nual meeting indicate that routine 
short course pre-operative radio-
therapy results in a signiﬁcant re-
duction in local recurrence and 
improved disease free survival 
at 3 years when compared with 
a highly selective post operative 
approach.
Preoperative radiotherapy, as an 
additional treatment to surgery in 
resectable rectal cancer, is supe-
rior to postoperative treatment in 
terms of dose-effectiveness and 
toxicity. Whether more sphinc-
ters can be preserved if neoadju-
vant radiotherapy with or without 
chemotherapy is used is still not 
proven.    www.ljm.org.ly   
page
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Palliative radiotherapy
Palliation of symptoms from pri-
mary lesion: Local recurrence of 
rectal cancer can be accompa-
nied by signs and symptoms that 
can greatly affect patients’ quality 
of life. Intractable pain from re-
currence in the presacral space 
and sacral nerve root entrapment 
often causes a great deal of dis-
tress. Continuous bleeding from 
a rectal tumour can require fre-
quent blood transfusions. The de-
cision to treat a local recurrence 
is based on several criteria and 
is guided by an evaluation of the 
patient’s beneﬁt in terms of im-
proved quality of life. Factors to 
consider include:
• Previous radiotherapy and time 
between treatment and recur-
rence.
• Tolerance of normal tissues.
• Volume of tissue to irradiate.
• Performance status of the pa-
tient.
Palliation of symptoms caused 
by distant metastases: Frequent 
sites of treatment include bones, 
lungs, and brain. Usually a short 
course of radiotherapy is sufﬁ-
cient (from a single treatment to 
2 weeks of treatment). Radiother-
apy is not advised, however, in 
situations where the patient has 
partial or complete obstruction of 
the intestine related to tumour. 
Instead, surgical correction in the 
form of colostomy should be a pri-
ority and radiation can be added 
later.
THE TARGETED THERAPY
The outcome for patients with ad-
vanced CRC has improved signif-
icantly as a result of the advanc-
es in chemotherapeutic agents. 
However, chemotherapies are 
restricted by both their lack of 
speciﬁcity and their frequent as-
sociation with potentially severe 
dose-limiting toxicities. There-
fore, better-tolerated treatments 
that speciﬁcally target the proc-
esses fundamental to tumorigen-
esis and metastasis are urgently 
required. Recent advances in the 
understanding of molecular biol-
ogy have led to the development 
of target-speciﬁc agents. Two 
targeted agents (recently ap-
proved by the FDA) are a human 
epidermal growth factor receptor 
(HER-1/EGFR)-targeted mAb, 
cetuximab (Erbitux®), and an 
anti-vascular endothelial growth 
factor (anti-VEGF) monoclonal 
antibody (mAb), bevacizumab 
(Avastin®), as ﬁrst- and second-
line metastatic CRC therapy, re-
spectively. These two agents are 
already having a signiﬁcant im-Libyan Journal of Medicine, Volume 1, 2006
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pact on metastatic CRC (MCRC) 
treatment strategies.
Cetuximab is a human:murine, chi-
meric anti-EGFR IgG1 MoAb that 
is indicated for use in combination 
with irinotecan for the treatment 
of patients with MCRC who have 
EGFR-expressing tumours that 
are refractory to irinotecan-based 
therapy or as monotherapy in iri-
notecan-intolerant patients with 
MCRC who have EGFR-express-
ing tumours. Preclinical studies 
have shown that when combined 
with cisplatin, paclitaxel, doxoru-
bicin, topotecan, gemcitabine, 5-
FU, or radiation the anti-tumour 
activity of cetuximab is potenti-
ated (51). Some 70% of colorec-
tal cancers express EGFR. (52) 
Cetuximab approval in the EU 
and USA was based on a pivotal 
European randomized phase II 
sudy (the BOND study) (53) and 
on two supporting clinical studies 
conducted in the USA (54). Bond 
study randomised patients with 
EGFR positive colorectal cancer 
who were irinotecan refractory 
to combination of irinotecan plus 
cetuximab or cetuximab alone. 
(53) The overall response rate 
and median time to progression 
were signiﬁcantly better in the 
combination arm. Overall survival 
was no different between treat-
ment arms, although this could 
be due to patients crossing over 
from single agent to multiagent 
therapy, as was permitted in the 
protocol. The major cetuximab 
speciﬁc toxicity was a reversible 
acneiform rash, which is common 
to all anti-EGFR agents. Interest-
ingly, patients who developed this 
characteristic rash were signiﬁ-
cantly more likely to respond to 
cetuximab.
Bevacizumab is a MAB targeting 
the VEGF that is now approved in 
the EU and the USA for use in the 
ﬁrst line treatment of advanced 
CRC. A phase III trial of the anti-
VEGF mabs, bevacizumab, has 
demonstrated the clinical util-
ity of VEGF targeting in patients 
with colorectal cancer. (55) A ran-
domised study of 815 patients 
with advanced colorectal cancer 
to Irinotecan plus 5-FU/FA (IFL) 
monotherapy alone or IFL plus 
bevacizumab. The IFL plus be-
vacizumab arm was superior for 
both response rate (45% vs 35%, 
P=0.0029) and median overall 
survival (20.3 vs 15.6 months, 
P=0.00003), with only relative 
minor additional toxicity. Mild to 
moderate hypertension was the 
most common toxicity identiﬁed, 
and was easily controlled. Also 
additional risk of bowel perfora-
tion has been noticed. This trial 
represents powerful evidence of     www.ljm.org.ly   
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the importance of VEGF-medi-
ated cellular signalling in the bi-
ology of colorectal cancer, and 
clearly indicates a signiﬁcant de-
velopment in the management of 
metastatic colorectal cancer.
For the last 40 years 5-FU has 
been the mainstay for metastatic 
CRC. In the past few years the 
introduction of more effective 
chemotheraoeutic agents and 
targeted agents with their prom-
ising activities and mild toxic-
ity proﬁles has raised the overall 
median survival from 12 months 
to 2 years. The adjuvant chemo-
therapy with 5-FU/FA (leucov-
orin) should be routinely offered 
to medically ﬁt patients with stage 
III colon cancer. Combination ad-
juvant treatment (eg. Oxaliplatin) 
may be considered in high risk 
patients but the role of adjuvant 
chemotherapy in stage II colon 
cancer is still controversial. Ad-
juvant therapy can be offered to 
high risk patients (patients with 
intestinal obstruction, perforation, 
T4 tumours, poorly differentiated 
tumours, extramural venous or 
lymphatic invasion, or perineural 
invasion and no other contraindi-
cation). In metastatic disease in 
terms of efﬁcacy and tolerability 
FOLFOX, FOLFIRI, and IFL plus 
Bevacizumab are the most ef-
fective ﬁrst line regimens. How-
ever, it has not been conﬁrmed 
yet which of these regimens is 
the most effective for individual 
patients, although bevacizumab 
plus FOLFOX or FOLFIRI is likely 
to have the most clinical beneﬁt. 
Surgery remains the primary cur-
ative treatment for rectal cancer 
and TME is still the standard sur-
gical procedure. 
Postoperative chemoradiation is 
accepted as standard adjuvant 
treatment for high risk stage II and 
III rectal cancer. In addition, short 
course preoperative radiotherapy 
is routinely used in some Euro-
pean countries (e.g. Nordic coun-
tries). Furthermore, preoperative 
chemoradiation is now increas-
ingly used to downstage locally 
advanced tumours to achieve mi-
croscopically complete resection 
with clear circumferential resec-
tion margin. Patients with distant 
metastases to lung or liver should 
be considered for resection of 
their metastases (Metastatecto-
my).
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